330 related articles for article (PubMed ID: 25740265)
1. Pharmacokinetics of QMF149 in Japanese versus Caucasian subjects: an open-label, randomized phase I study.
Shimada S; Vaidya S; Khindri S; Tashiro N; Cheng Y; Hara H; Majumdar T; Woessner R; Furihata K; Kobayashi K
Int J Clin Pharmacol Ther; 2015 May; 53(5):398-407. PubMed ID: 25740265
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics of indacaterol and mometasone furoate delivered alone or in a free or fixed dose combination in healthy subjects.
Vaidya SS; Khindri S; Calder N; Machineni S; Hara H; Majumdar T; Febbraro S; Fuhr R; Woessner R
Pulm Pharmacol Ther; 2016 Apr; 37():30-6. PubMed ID: 26845343
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics of indacaterol, glycopyrronium and mometasone furoate administered as an inhaled fixed-dose combination in Japanese and Caucasian healthy subjects.
Inoue S; Vaidya S; Tillmann HC; Sakita Y; Machineni S; Heudi O; Furihata K
BMC Pulm Med; 2021 Jan; 21(1):18. PubMed ID: 33413291
[TBL] [Abstract][Full Text] [Related]
4. Lung Delivery of Indacaterol and Mometasone Furoate Following Inhalation of QMF149 in Healthy Volunteers.
Vaidya SS; Khindri S; Maahs S; Machineni S; Hara H; Juan A; Kaiser G
Clin Pharmacol Drug Dev; 2016 Jul; 5(4):285-95. PubMed ID: 27310329
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics of mometasone furoate delivered via two dry powder inhalers.
Vaidya S; Ziegler D; Tanase AM; Malmqvist U; Kanniess F; Hederer B; Hosoe M
Pulm Pharmacol Ther; 2021 Oct; 70():102019. PubMed ID: 33771722
[TBL] [Abstract][Full Text] [Related]
6. Effect of once-daily indacaterol maleate/mometasone furoate on exacerbation risk in adolescent and adult asthma: a double-blind randomised controlled trial.
Beasley RW; Donohue JF; Mehta R; Nelson HS; Clay M; Moton A; Kim HJ; Hederer BM
BMJ Open; 2015 Feb; 5(2):e006131. PubMed ID: 25649209
[TBL] [Abstract][Full Text] [Related]
7. Population Pharmacokinetic Analysis of Indacaterol/Glycopyrronium/Mometasone Furoate After Administration of Combination Therapies Using the Breezhaler
Bartels C; Jain M; Yu J; Tillmann HC; Vaidya S
Eur J Drug Metab Pharmacokinet; 2021 Jul; 46(4):487-504. PubMed ID: 34024035
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics and safety of indacaterol and glycopyrronium (IND/GLY) following repeated once daily inhalation from a fixed-dose combination in healthy Chinese subjects
.
Ren S; Sechaud R; Su Z; Tillmann HC; Hara H; Tan X; Hou J; Woessner R; Zhao R
Int J Clin Pharmacol Ther; 2017 Feb; 55(2):147-155. PubMed ID: 27841152
[TBL] [Abstract][Full Text] [Related]
9. Efficacy, safety and pharmacokinetics of indacaterol in Caucasian and Japanese patients with chronic obstructive pulmonary disease: a comparison of data from two randomized, placebo-controlled studies.
Hosoe M; Woessner R; Matsushima S; Lawrence D; Kramer B
Clin Drug Investig; 2011; 31(4):247-55. PubMed ID: 21184620
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics of indacaterol, glycopyrronium and mometasone furoate following once-daily inhalation as a combination in healthy subjects.
Vaidya S; Jauernig J; Ethell B; Abdallah N; Machineni S; Drollmann A; Heudi O; Last S; Hahn M; Radhakrishnan R; Ignatenko S; Tillmann HC
Pulm Pharmacol Ther; 2020 Oct; 64():101964. PubMed ID: 33035700
[TBL] [Abstract][Full Text] [Related]
11. Lung function, pharmacokinetics, and tolerability of inhaled indacaterol maleate and acetate in asthma patients.
Miller D; Vaidya S; Jauernig J; Ethell B; Wagner K; Radhakrishnan R; Tillmann HC
Respir Res; 2020 Sep; 21(1):248. PubMed ID: 32967685
[TBL] [Abstract][Full Text] [Related]
12. Indacaterol acetate/mometasone furoate provides sustained improvements in lung function compared with salmeterol xinafoate/fluticasone propionate in patients with moderate-to-very-severe COPD: results from a Phase II randomized, double-blind 12-week study.
Beeh KM; Kirsten AM; Tanase AM; Richard A; Cao W; Hederer B; Beier J; Kornmann O; van Zyl-Smit RN
Int J Chron Obstruct Pulmon Dis; 2018; 13():3923-3936. PubMed ID: 30584293
[TBL] [Abstract][Full Text] [Related]
13. A randomized, double-blind study to compare the efficacy and safety of two doses of mometasone furoate delivered via Breezhaler® or Twisthaler® in patients with asthma.
Buhl R; Tanase AM; Hosoe M; Cao W; Demin I; Bartels C; Jauernig J; Ziegler D; Patalano F; Hederer B; Kanniess F; Tillmann HC
Pulm Pharmacol Ther; 2020 Jun; 62():101919. PubMed ID: 32387408
[TBL] [Abstract][Full Text] [Related]
14. Once-daily, single-inhaler mometasone-indacaterol-glycopyrronium versus mometasone-indacaterol or twice-daily fluticasone-salmeterol in patients with inadequately controlled asthma (IRIDIUM): a randomised, double-blind, controlled phase 3 study.
Kerstjens HAM; Maspero J; Chapman KR; van Zyl-Smit RN; Hosoe M; Tanase AM; Lavecchia C; Pethe A; Shu X; D'Andrea P;
Lancet Respir Med; 2020 Oct; 8(10):1000-1012. PubMed ID: 32653074
[TBL] [Abstract][Full Text] [Related]
15. Bioequivalence studies of inhaled indacaterol maleate in healthy Chinese volunteers under gastrointestinal non-blocking or blocking with concomitant charcoal administration.
Zou C; Yang Q; Yang S; Zhang X; Yang X; Huang Z; Pei Q; Huang J; Yang G
Pulm Pharmacol Ther; 2020 Apr; 61():101902. PubMed ID: 32045673
[TBL] [Abstract][Full Text] [Related]
16. Dose bridging data for mometasone furoate in once-daily fixed-dose inhaled combinations of mometasone furoate/indacaterol and mometasone furoate/ indacaterol/glycopyrronium in patients with asthma.
Buhl R; Nikolaev I; Tillmann HC; Vaidya S; Bartels C; Jain M; Jauernig J; Kerstjens HAM
Pulm Pharmacol Ther; 2021 Oct; 70():102068. PubMed ID: 34329722
[TBL] [Abstract][Full Text] [Related]
17. Once-daily mometasone plus indacaterol versus mometasone or twice-daily fluticasone plus salmeterol in patients with inadequately controlled asthma (PALLADIUM): a randomised, double-blind, triple-dummy, controlled phase 3 study.
van Zyl-Smit RN; Krüll M; Gessner C; Gon Y; Noga O; Richard A; de Los Reyes A; Shu X; Pethe A; Tanase AM; D'Andrea P;
Lancet Respir Med; 2020 Oct; 8(10):987-999. PubMed ID: 32653075
[TBL] [Abstract][Full Text] [Related]
18. Comparison of the systemic bioavailability of mometasone furoate after oral inhalation from a mometasone furoate/formoterol fumarate metered-dose inhaler versus a mometasone furoate dry-powder inhaler in patients with chronic obstructive pulmonary disease.
Kosoglou T; Hubbell J; Xuan F; Cutler DL; Meehan AG; Kantesaria B; Wittmer BA
Int J Chron Obstruct Pulmon Dis; 2013; 8():107-16. PubMed ID: 23525511
[TBL] [Abstract][Full Text] [Related]
19. Fixed-dose combination of indacaterol/glycopyrronium/mometasone furoate once-daily versus salmeterol/fluticasone twice-daily plus tiotropium once-daily in patients with uncontrolled asthma: A randomised, Phase IIIb, non-inferiority study (ARGON).
Gessner C; Kornmann O; Maspero J; van Zyl-Smit R; Krüll M; Salina A; Gupta P; Bostel S; Fucile S; Conde LG; Pfister P
Respir Med; 2020; 170():106021. PubMed ID: 32843164
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of inhaled once-daily low-dose indacaterol acetate/mometasone furoate in patients with inadequately controlled asthma: Phase III randomised QUARTZ study findings.
Kornmann O; Mucsi J; Kolosa N; Bandelli L; Sen B; Satlin LC; D'Andrea P
Respir Med; 2020 Jan; 161():105809. PubMed ID: 32056721
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
